- Home
- BDTX vs JRVR Comparison
BDTX vs JRVR Comparison
Compare BDTX & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | JRVR |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 209.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BDTX | JRVR |
|---|---|---|
| Price | $1.88 | $3.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $9.67 | $7.33 |
| AVG Volume (30 Days) | ★ 510.7K | 252.2K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.64% |
| EPS Growth | ★ 130.71 | 125.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $687,614,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $3.52 |
| 52 Week High | $4.94 | $7.20 |
Technical Indicators
Market Signals| Indicator | BDTX | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 29.24 |
| Support Level | $1.76 | N/A |
| Resistance Level | $1.90 | $4.26 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 14.10 | 9.45 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.